ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal
11 Octobre 2021 - 07:11PM
Business Wire
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME
eligible), a next-generation biotech company dedicated to the
discovery and development of innovative therapies, announced today
that it is initiating discussions with IRIS Pharma, a world leader
in preclinical and clinical ophthalmology contract research, with a
view to a possible strategic deal, in which IRIS Pharma's contract
research business would remain separate from the biotech research
and development activity and to continue to grow.
These exchanges follow the positive clinical results which led
to the disappearance of visual blur related to corneal deposits in
a patient suffering from LCAT activity deficiency within the
framework of a Temporary Use Authorization, and the initial
preclinical results in uveitis that indicate the major therapeutic
potential of bio-HDL in ophthalmology, and more broadly the role of
lipids in ocular pathologies.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211011005608/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024